Bettapharma
Bettapharma
Bettapharma mainly providing customers with products such as Ectinib hydrochlorid
Beda Pharmaceuticals is an innovative drug developer in the fields of malignancy, ophthalmology, autoimmune diseases and diabetes, mainly providing customers with products such as Ectinib hydrochloride (Kemena), new antineoplastic drug CM082 and other products, including six national Class I and Class II new drugs, and 14 national Class III and Class IV new drugs in the pipeline.
- All
- News
- Analysis
- Research
In depth
Briefing Jan 13, 2022 10:05 AM
· Healthcare
West Lake Omei won hundreds of millions of yuan of pre-A round of financing to help clinical diagnosis and AI new drug research and development based on proteome big data
Briefing Jan 12, 2022 09:28 AM
· Healthcare
Zhenge biology obtained US $100 million in round C financing, led by Goldman Sachs and Sofina
Apr 22, 2021 03:11 PM
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Real Estate, Industrials, FinancialsTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Briefing Nov 29, 2021 07:59 PM
· Healthcare
Boten Co., Ltd.: direnavir API has passed who PQ certification
Briefing Aug 31, 2021 08:59 PM
TECO shares: obtained an invention patent certificate
In depth
Healthcare
Dada group's revenue rose nearly 30% in the third quarter, and JD's "hour purchase" cont
Looking forward to the fourth quarter of 2021, dada Group expects its total revenue to be between 2 billion yuan and 2.1 billion yuan. On the premise that the last kilometer of dada express delivery service is consistent with the comparable basis, the total revenue in the fourth quarter of 2021 will achieve a year-on-year increase of 88% to 97%.
Nov 24, 2021 11:42 AM
Briefing Jul 07, 2021 03:24 PM
· Healthcare
The first bank of China fund to release its second Quarterly Report
Briefing Dec 11, 2020 08:17 PM
· Healthcare
Beida pharmaceutical: the three shareholders intend to reduce the shares of the company no more than 2.31%
See more
Related Companies
EqualOcean Analysis
- Wuxi Apptec Embraces a More Health-Conscious China
- Four Growing Stocks to Watch in the Dynamic Chinese Market
- Genetron Health's Self-Developed Mutation Capsule Differentiates It from Others
- Black Swans and Breakthroughs: China's Top 50 Innovative Public Firms in 2020
- China Speed: Two COVID-19 Vaccines Recognized by WHO
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.